Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
By A. El-Khoueiry, B. Sangro, T. Yau, T. Crocenzi, M. Kudo, Chiun Hsu, Tae-You Kim, S. Choo, J. Trojan, T. Welling and 11 more. The Lancet, 2017
3,695 citations recorded by the source corpus.
Summary Background For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and efficacy of nivolumab, a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor, in patients with advanced hepatocellular carcinoma with or without chronic viral hepatitis. Methods We did a phase 1/2, open-label, non-comparative, dose escalation and expansion trial (CheckMate 040) of nivolumab in adults (≥18 years) with histologically confirmed advanced hepatocellular carcinoma with or without hepatitis C or B (HCV or HBV) infection. Previous sorafenib treatment was allowed. A dose-escalation phase was conducted at seven hospitals or academic centres in four countries or territories (USA, Spain, Hong Kong, and Singapore) and a dose-expansion phase was conducted at an additional 39 sites in 11 countries (Canada, UK, Germany, Italy, Japan, South Korea, Taiwan). At screening, eligible patients had Child-Pugh scores of 7 or less (Child-Pugh A or B7) for the dose-escalation phase and 6 or less (Child-Pugh A) for the dose-expansion phase, and an Eastern Cooperative Oncology Group performance status of 1 or less. Patients with HBV infection had to be receiving effective antiviral therapy (viral load <100 IU/mL); antiviral therapy was not required for patients with HCV infection. We excluded patients previously treated with an agent targeting T-cell costimulation or checkpoint pathways. Patients received intravenous nivolumab 0·1–10 mg/kg every 2 weeks in the dose-escalation phase (3+3 design). Nivolumab 3 mg/kg was given every 2 weeks in the dose-expansion phase to patients in four cohorts: sorafenib untreated or intolerant without viral hepatitis, sorafenib progressor without viral hepatitis, HCV infected, and HBV infected. Primary endpoints were safety and tolerability for the escalation phase and objective response rate (Response Evaluation Criteria In Solid Tumors version 1.1) for the expansion phase. This study is registered with ClinicalTrials.gov, number NCT01658878. Findings Between Nov 26, 2012, and Aug 8, 2016, 262 eligible patients were treated (48 patients in the dose-escalation phase and 214 in the dose-expansion phase). 202 (77%) of 262 patients have completed treatment and follow-up is ongoing. During dose escalation, nivolumab showed a manageable safety profile, including acceptable tolerability. In this phase, 46 (96%) of 48 patients discontinued treatment, 42 (88%) due to disease progression. Incidence of treatment-related adverse events did not seem to be associated with dose and no maximum tolerated dose was reached. 12 (25%) of 48 patients had grade 3/4 treatment-related adverse events. Three (6%) patients had treatment-related serious adverse events (pemphigoid, adrenal insufficiency, liver disorder). 30 (63%) of 48 patients in the dose-escalation phase died (not determined to be related to nivolumab therapy). Nivolumab 3 mg/kg was chosen for dose expansion. The objective response rate was 20% (95% CI 15–26) in patients treated with nivolumab 3 mg/kg in the dose-expansion phase and 15% (95% CI 6–28) in the dose-escalation phase. Interpretation Nivolumab had a manageable safety profile and no new signals were observed in patients with advanced hepatocellular carcinoma. Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma. Funding Bristol-Myers Squibb.
Subfields: Hepatology, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/ab58459951e97a213aab9dd52b5171e5ba371b35
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
- J. Llovet
- V. Mazzaferro
- Alejandro Forner1 , 2
- Andrew X. Zhu
- Peter R. Galle
- L. Kulik
- R. Finn
- Lewis R. Roberts
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features (2017, neutral): “Variable Training set (n=225) Validation Set (n=131) TCGA set (n=190) Median age (IQR) 66 (61-72) 66 (55-71) 62 (52-70) Gender, male (%) 178 (79) 96 (73) 123 (65) Etiology (%) Hepatitis C 101 (46) 64 (50) N/A Hepatitis B 48 (21) 39 (30) N/A Alcohol 33 (15) 6 (5) N/A Others 38 (17) 19 (15) Child-Pugh”
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, background): “Promising signals of efficacy have been reported in large phase II studies with the checkpoint inhibitor nivolumab.(565) So far, no proof-of-concept biomarker-enriched study has yet demonstrated efficacy for”
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations (2018, background): “Recently on September 22, 2017, nivolumab 3 mg/kg every 2 weeks was approved in advanced hepatocellular carcinoma (HCC) refractory to sorafenib in the phase I/ II CheckMate 040 trial [56].”
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. (2019, background): “0%).(8,9,23,24) Pembrolizumab also led to a shift toward better categories of best overall response compared with placebo; 10% fewer patients in the pembrolizumab arm had PD, and 14% more had an objective response.”
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2019, background): “(170) The anti-PD-1 monoclonal antibody, nivolumab, has demonstrated significant activity in a single-arm dose-escalation and -expansion study that included both sorafenib naïve and sorafenib-pretreated patients with various underlying etiology.(171) A total of 182 sorafenib-experienced patients wer”
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence (2020, methodology): “Nivolumab was granted approval for this group of patients via an accelerated process on 22 September 2017, based on the ORR from this trial [45] (Category 2A).”